{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T19:17:06Z","timestamp":1726168626296},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1984,1,1]],"date-time":"1984-01-01T00:00:00Z","timestamp":441763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1984]]},"DOI":"10.1007\/bf00427772","type":"journal-article","created":{"date-parts":[[2004,11,10]],"date-time":"2004-11-10T09:29:09Z","timestamp":1100078949000},"page":"194-198","source":"Crossref","is-referenced-by-count":12,"title":["Serum neuroleptic concentrations and clinical response: A radioreceptor assay investigation of acutely psychotic patients"],"prefix":"10.1007","volume":"82","author":[{"given":"L. T.","family":"Kucharski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Tune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0165-1781(79)90026-X","volume":"1","author":"HM Calil","year":"1979","unstructured":"Calil HM, Avery DH, Hollister LE, Creese I, Snyder SH (1979) Serum levels of neuroleptics measured by dopamine radioreceptor assay and some clinical observations. Psychiatr Res 1:39?44","journal-title":"Psychiatr Res"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00435313","volume":"70","author":"BM Cohen","year":"1980","unstructured":"Cohen BM, Lipinski JR, Pope HG, Harris PO, Altesman RI (1980) Neuroleptic blood levels and clinical effect. Psychopharmacology 70:191?193","journal-title":"Psychopharmacology"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/270180a0","volume":"270","author":"I Creese","year":"1977","unstructured":"Creese I, Snyder SH (1977) A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature 270:180?182","journal-title":"Nature"},{"key":"CR4","first-page":"27","volume":"14","author":"DL Garver","year":"1978","unstructured":"Garver DL, Dekirmenjian H, Davis JM (1978) Phenothiazine red cell levels and clinical response. Psychopharmacol Bull 14:27?29","journal-title":"Psychopharmacol Bull"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1176\/ajp.134.3.304","volume":"134","author":"DL Garver","year":"1977","unstructured":"Garver DL, Dekirmenjian H, Davis JM, Casper R, Ericksen S (1977) Neuroleptic blood levels and therapeutic response: preliminary observations with red blood cell bound butaperazine. Am J Psychiatry 134:304?307","journal-title":"Am J Psychiatry"},{"key":"CR6","volume-title":"Fundamental statistics for psychology and education","author":"JP Guilford","year":"1950","unstructured":"Guilford JP (1950) Fundamental statistics for psychology and education. McGraw-Hill, New York, NY"},{"key":"CR7","volume-title":"NCDEU Assessment Manual for Psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W (1976) NCDEU Assessment Manual for Psychopharmacology. US Dept. of Health, Education and Welfare, Washington DC"},{"key":"CR8","first-page":"1184","volume":"301","author":"DV Jeste","year":"1979","unstructured":"Jeste DV, Rosenblatt JR, Wagner RL, Wyatt RJ (1979) High serum levels in tardive dyskinesia. New Engl J Med 301:1184","journal-title":"New Engl J Med"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00005053-198004000-00004","volume":"168","author":"LT Kucharski","year":"1980","unstructured":"Kucharski LT, Smith JM, Dunn DD (1980) Tardive dyskinesia and hospital discharge. J Nerv Ment Dis 168:215?218","journal-title":"J Nerv Ment Dis"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2125.1974.tb00281.x","volume":"1","author":"AVP MacKay","year":"1974","unstructured":"MacKay AVP, Healey AF, Baker J (1974) The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxide metabolites in a large population of chronic schizophrenics. Brit J Clin Pharmacol 1:425?430","journal-title":"Brit J Clin Pharmacol"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1176\/ajp.138.11.1514-a","volume":"138","author":"JR Magliozzi","year":"1981","unstructured":"Magliozzi JR, Hollister LE, Arnold KV, Earle GM (1981) The relationship of serum haloperidol levels to clinical response in schizophrenic patients. Am J Psychiatry 138:365?367","journal-title":"Am J Psychiatry"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/archpsyc.1978.01770330055004","volume":"35","author":"PRA May","year":"1978","unstructured":"May PRA, Van Putten T (1978) Plasma levels of chlorpromazine in schizophrenia. Arch Gen Psychiatry 35:1081?1087","journal-title":"Arch Gen Psychiatry"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799?812","journal-title":"Psychol Rep"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1192\/bjp.131.2.172","volume":"131","author":"IT Phillipson","year":"1977","unstructured":"Phillipson IT, McKeown JM, Baker J, Healey AF (1977) Correlation between plasma chlorpromazine and its metabolites and clinical rating in patients with actual relapse of schizophrenic and paranoid psychosis. Br J Psychiatry 131:172?185","journal-title":"Br J Psychiatry"},{"key":"CR15","first-page":"191","volume":"73","author":"R Rimon","year":"1981","unstructured":"Rimon R, Averbuch I, Roxick P, Fijman-Danilovich L, Kara T, Dasberg H, Ebstein RP, Belmaker RH (1981) Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high dose therapy of resistant schizophrenic patients. Pscychopharmacology 73:191?199","journal-title":"Pscychopharmacology"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1176\/ajp.133.6.646","volume":"133","author":"L Rivera-Calimlim","year":"1976","unstructured":"Rivera-Calimlim L, Nassralah H, Strauss J, Lasagna L (1976) Clinical response and plasma levels: effects of dose, dosage schedule and drug interaction on plasma chlorpromazine levels. Am J Psychiatry 133:646?652","journal-title":"Am J Psychiatry"},{"key":"CR17","first-page":"78","volume":"16","author":"JE Rosenblatt","year":"1980","unstructured":"Rosenblatt JE, Pary RJ, Bigelow LB (1980) Measurement of serum neuroleptic concentration by radioreceptor assay: concurrent assessment of clinical response and toxicity. Psychopharmacol Bull 16:78?80","journal-title":"Psychopharmacol Bull"},{"key":"CR18","first-page":"153","volume":"3","author":"JE Rosenblatt","year":"1979","unstructured":"Rosenblatt JE, Pert CB, Colison J, van Kammen DP, Scott R, Bunney WE (1979) Measurement of serum neuroleptic concentration by radioreceptor assay: concurrent assessment of clinical psychosis ratings. Commun Psychopharmacol 3:153?158","journal-title":"Commun Psychopharmacol"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00422150","volume":"32","author":"G Sakalis","year":"1973","unstructured":"Sakalis G, Chan TL, Gershon S, Park S (1973) The possible role of metabolites in the therapeutic response to chlorpromazine treatment. Psychopharmacologia 32:279?284","journal-title":"Psychopharmacologia"},{"key":"CR20","first-page":"157","volume":"1","author":"G Sakalis","year":"1977","unstructured":"Sakalis G, Chan TL, Sathananthan G, Schooler N, Goldberg S, Gershon S (1977) Relationships among clinical response, extrapyramidal syndrome and plasma chlorpromazine and metabolic ratios. Commun Psychopharmacol 1:157?166","journal-title":"Commun Psychopharmacol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/cpt1972136931","volume":"13","author":"G Sakalis","year":"1972","unstructured":"Sakalis G, Curry SH, Mould GP, Lader MH (1972) Physiologic and clinical effects of chlorpromazine and their relationship to plasma level. Clin Pharmacol Ther 13:931?946","journal-title":"Clin Pharmacol Ther"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1001\/archpsyc.1979.01780050089011","volume":"36","author":"RC Smith","year":"1979","unstructured":"Smith RC, Crayton J, Dekirmenjian H, Klass D, Davis JM (1979) Blood levels of neuroleptic drugs in non-responding chronic schizophrenic patients. Arch Gen Psychiatry 36:579?584","journal-title":"Arch Gen Psychiatry"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1176\/ajp.137.2.187","volume":"137","author":"LE Tune","year":"1980","unstructured":"Tune LE, Creese I, DePaulo JR, Slavney PR, Coyle JT, Snyder SH (1980) Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia. Am J Psychiatry 137:187?190","journal-title":"Am J Psychiatry"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005053-198101000-00009","volume":"169","author":"LE Tune","year":"1981","unstructured":"Tune LE, Creese I, DePaulo JR, Slavney PR, Coyle JT, Snyder SH (1981) Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizopherenic patients. J Nerv Ment Dis 169:60?63","journal-title":"J Nerv Ment Dis"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1017\/S0033291700015841","volume":"6","author":"DH Wiles","year":"1976","unstructured":"Wiles DH, Kolakowski T, McNeilly AS, Mandelbrote BM, Gelder MG (1976) Clinical significance of plasma chlorpromazine levels. I. Plasma levels of drug, some of its metabolites and prolactin during acute treatment. Psychol Med 6:407?415","journal-title":"Psychol Med"},{"key":"CR26","first-page":"5","volume":"12","author":"RJ Wyatt","year":"1976","unstructured":"Wyatt RJ (1976) Biochemistry of schizophrenia, part IV, The neuroleptics, their mechanism of action. Psychopharm Bull 12:5?50","journal-title":"Psychopharm Bull"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00427772.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00427772\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00427772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T22:37:52Z","timestamp":1554849472000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00427772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1984]]}},"alternative-id":["BF00427772"],"URL":"https:\/\/doi.org\/10.1007\/bf00427772","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1984]]}}}